Enterobacter aerogenes is a rod-shaped, gram-negative bacterium that lives naturally in the human gut and in the environment. It typically causes no harm in healthy people but can trigger serious infections in hospitalized or immunocompromised patients, particularly when it enters the bloodstream, lungs, or urinary tract. In 2017, the bacterium was officially reclassified and renamed Klebsiella aerogenes, though the older name remains widely used in clinical settings and textbooks.
Basic Characteristics
This bacterium belongs to the family Enterobacteriaceae, a large group of organisms that includes well-known species like E. coli and Salmonella. It is rod-shaped, does not form spores, and stains pink on a Gram stain (gram-negative), meaning it has a thin cell wall surrounded by an outer membrane. That outer membrane is part of what makes gram-negative bacteria harder to kill with certain antibiotics.
The bacterium is motile, propelling itself with tiny hair-like structures called peritrichous flagella that cover its surface. It is also a facultative anaerobe, which means it can grow with or without oxygen. This metabolic flexibility helps it survive in a wide range of environments, from the oxygen-rich respiratory tract to the low-oxygen interior of the intestines.
Where It Lives
Enterobacter aerogenes is part of the normal microbial community in the human gastrointestinal tract. Most people carry it without any symptoms. It also exists in soil, water, sewage, and food, making it a common environmental organism. In hospitals, it can colonize surfaces, medical equipment, and the hands of healthcare workers, which is a major factor in how it spreads between patients.
Why the Name Changed
For decades, this bacterium was classified under the genus Enterobacter. But genetic analysis revealed it was more closely related to Klebsiella species. The formal reclassification happened in 2017 when researchers determined that Enterobacter aerogenes and Klebsiella mobilis shared the same reference strain (known as a nomenclatural type), making them essentially the same organism. Under the rules of bacterial naming, this meant the bacterium had to be moved into the Klebsiella genus. It is now officially called Klebsiella aerogenes, though many clinicians and lab reports still use the original name.
Infections It Causes
In healthy people, this bacterium rarely causes disease. It becomes a problem primarily in hospital settings, where it is one of the more common causes of healthcare-associated infections. The bacterium is isolated from the respiratory tract, urinary tract, bloodstream, and gastrointestinal tract of hospitalized patients.
Specific infection types include:
- Ventilator-associated pneumonia: one of the most significant infections linked to this organism, occurring in patients on mechanical breathing support
- Urinary tract infections: often related to the use of urinary catheters
- Bloodstream infections (bacteremia): most cases are acquired in hospitals, frequently in intensive care units, and the source is often a central line, arterial catheter, or an infection that has spread from another organ
- Surgical site infections and bone or joint infections: typically in patients with complex surgical histories
- Post-transplant pneumonia: this species is a notable cause of early lung infections after lung transplantation
Who Is Most at Risk
The people most vulnerable to Enterobacter aerogenes infections are those already weakened by other medical conditions or invasive procedures. Risk factors include chronic obstructive pulmonary disease, diabetes, alcohol use disorder, cancer, and neurological diseases. Patients in intensive care units face the highest risk, especially those with central venous catheters, arterial lines, or mechanical ventilators.
Elderly and debilitated patients deserve special mention because their infections may not produce the typical signs of a strong immune response, like high fever or elevated white blood cell counts. This can make the infection harder to recognize early, delaying treatment.
Antibiotic Resistance
One of the most clinically important features of this bacterium is its ability to resist antibiotics. It naturally produces an enzyme called AmpC beta-lactamase, which breaks down many commonly used antibiotics. At baseline, this enzyme is produced at low levels and makes the bacterium resistant to ampicillin, amoxicillin, and first- and second-generation cephalosporins. Those drugs are essentially useless against it from the start.
The bigger concern is what happens during treatment. When exposed to certain antibiotics, particularly third-generation cephalosporins like ceftriaxone, the bacterium can ramp up production of AmpC dramatically. This happens through a process called derepression, where subpopulations of bacteria that overproduce the enzyme are naturally selected during antibiotic exposure. A patient may initially test as susceptible to a drug on routine lab testing, only to develop resistance during the course of treatment. This makes the organism particularly tricky to manage.
Because of this risk, stronger antibiotics called carbapenems have traditionally been used for serious infections, since their chemical structure resists breakdown by AmpC enzymes. However, carbapenem-resistant strains have also emerged, driven by additional resistance genes like KPC and metallo-beta-lactamases. Infections caused by these highly resistant strains carry significantly higher mortality rates and leave very few treatment options.
How Hospitals Prevent Its Spread
Because most Enterobacter aerogenes infections are acquired in healthcare settings, prevention centers on breaking the chain of transmission between patients. Hand washing or the use of alcohol-based hand gels between patient contacts is the single most effective measure, especially in ICUs.
When a multidrug-resistant strain is identified, hospitals implement contact precautions, meaning healthcare workers wear gowns and gloves when entering the patient’s room, and the patient may be placed in isolation. During outbreaks in ICUs, barrier protection protocols are escalated further. Patients who have recently been hospitalized outside the country may be screened with rectal cultures and placed on contact precautions until results come back, since resistant strains vary by region.
Antibiotic stewardship also plays a central role. Limiting unnecessary antibiotic use, keeping surgical prophylaxis to 24 hours or less, and avoiding prolonged courses all reduce the selective pressure that drives resistance. Given how readily this bacterium develops resistance during treatment, careful antibiotic selection based on susceptibility testing is critical for both individual patients and the broader goal of slowing the spread of resistant strains.